Table 1 Sequential cohort patient characteristics
IMRT | 3DCRT | |||
|---|---|---|---|---|
(N = 117) | (N = 83) | p | ||
Age | mean (SD) | 59.9 (9.0) | 58.8 (9.5) | 0.41 |
Gender | F (%) | 18 (15.4) | 19 (22.9) | 0.20 |
M | 99 (84.6) | 64 (77.1) | ||
T stage | 1 or 0* (%) | 28 (23.9) | 14 (16.9) | 0.52 |
2 | 42 (35.9) | 30 (36.1) | ||
3 | 28 (23.9) | 20 (24.1) | ||
4 | 19 (16.2) | 19 (22.9) | ||
N Stage | 0 (%) | 15 (12.8) | 12 (14.5) | 0.28 |
1 | 16 (13.6) | 18 (21.7) | ||
2 | 83 (70.9) | 51 (61.4) | ||
3 | 3 (2.6) | 2 (2.4) | ||
Stage | III (%) | 20 (17.1) | 19 (22.9) | 0.37 |
IV | 97 (82.9) | 64 (77.1) | ||
Primary site | Tongue Base (%) | 41 (35.0) | 36 (43.4) | 0.24 |
Tonsil, soft palate | 76 (65.0) | 47 (56.6) | ||
Concomitant | Cisplatin (%) | 85 (72.6) | 62 (74.7) | 0.01 |
Cetuximab | 12 (10.3) | 0 (0) | ||
No | 20 (17.1) | 21 (25.3) | ||
Assessments | 3 months (%) | 95.7 | 72 | <0.0001 |
6 | 98.2 | 90.2 | 0.02 | |
12 | 92.2 | 90.8 | 0.96 | |
24 | 91.2 | 95.3 | 0.49 |